Your browser is no longer supported. Please, upgrade your browser.
Settings
REPH Recro Pharma, Inc. daily Stock Chart
REPH [NASD]
Recro Pharma, Inc.
Index- P/E- EPS (ttm)-3.27 Insider Own2.00% Shs Outstand21.96M Perf Week-0.10%
Market Cap219.16M Forward P/E34.90 EPS next Y0.29 Insider Trans-19.27% Shs Float20.95M Perf Month9.91%
Income-69.20M PEG- EPS next Q-0.42 Inst Own70.60% Short Float3.46% Perf Quarter18.95%
Sales82.90M P/S2.64 EPS this Y-76.10% Inst Trans0.27% Short Ratio3.01 Perf Half Y28.11%
Book/sh-0.87 P/B- EPS next Y145.30% ROA-40.00% Target Price12.30 Perf Year80.80%
Cash/sh2.64 P/C3.78 EPS next 5Y- ROE- 52W Range5.07 - 10.69 Perf YTD40.56%
Dividend- P/FCF- EPS past 5Y-54.30% ROI-159.90% 52W High-6.64% Beta-0.26
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin43.20% 52W Low96.84% ATR0.40
Employees255 Current Ratio3.60 Sales Q/Q28.70% Oper. Margin-47.70% RSI (14)53.65 Volatility3.38% 4.22%
OptionableYes Debt/Eq- EPS Q/Q86.10% Profit Margin-83.60% Rel Volume1.20 Prev Close10.14
ShortableYes LT Debt/Eq- EarningsAug 09 BMO Payout- Avg Volume240.48K Price9.98
Recom1.80 SMA200.04% SMA505.02% SMA20022.57% Volume287,218 Change-1.58%
Jan-31-19Resumed Janney Buy $13
Feb-14-18Initiated Oppenheimer Outperform $19
Dec-19-16Initiated Piper Jaffray Overweight $12
Nov-14-16Initiated Aegis Capital Buy $21
Oct-03-16Resumed Brean Capital Buy
Sep-16-16Initiated ROTH Capital Buy
Nov-24-15Resumed H.C. Wainwright Buy $14
Sep-02-15Initiated H.C. Wainwright Buy $19
Jun-18-15Reiterated Brean Capital Buy $26 → $28
Apr-14-15Reiterated MLV & Co Buy $12 → $22
Jun-12-14Initiated Aegis Capital Buy $40
Mar-20-14Initiated Brean Capital Buy $26
Jun-26-19 09:42PM  Did Hedge Funds Drop The Ball On Recro Pharma Inc (REPH)? Insider Monkey
Jun-25-19 12:02PM  Should You Worry About Recro Pharma, Inc.'s (NASDAQ:REPH) CEO Salary Level? Simply Wall St.
11:59AM  What Did Recro Pharma, Inc.'s (NASDAQ:REPH) CEO Take Home Last Year? Simply Wall St.
Jun-17-19 01:37PM  Edited Transcript of REPH earnings conference call or presentation 10-May-19 12:00pm GMT Thomson Reuters StreetEvents
Jun-14-19 02:59PM  7 Top-Rated Biotech Stocks to Invest In Today InvestorPlace
Jun-12-19 01:42PM  Update: Recro Pharma (NASDAQ:REPH) Stock Gained 68% In The Last Year Simply Wall St.
Jun-07-19 03:01PM  7 A-Rated Stocks to Buy Under $10 InvestorPlace
May-30-19 07:00AM  Recro Pharma to Present at Upcoming Investor Conferences GlobeNewswire
May-22-19 03:47PM  Catalyst Pharma (CPRX) Rides on Successful Launch of Firdapse Zacks
May-21-19 08:52AM  Catalent Acquires Gene Therapy Leader Paragon Bioservices Zacks
May-20-19 08:14AM  New Strong Buy Stocks for May 20th Zacks
May-14-19 02:36PM  Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start Zacks
May-10-19 08:35AM  Recro Pharma (REPH) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:25AM  Recro Pharma: 1Q Earnings Snapshot Associated Press
07:00AM  Recro Pharma Reports First Quarter 2019 Financial Results GlobeNewswire
May-08-19 08:57AM  Recro Pharma, Inc. (REPH): Here are Midwood Capital Managements Thoughts On The Pharmaceutical Company Insider Monkey
08:01AM  Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates Zacks
May-06-19 08:11AM  Small Drug Stocks Outlook: Near-Term Prospects Encouraging Zacks
07:00AM  Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019 GlobeNewswire
May-01-19 10:32AM  Recro Pharma (REPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks
Apr-26-19 05:33AM  Here is What Artko Capital Thinks About Recro Pharma, Inc. (REPH) Insider Monkey
Apr-24-19 07:24AM  Recro Pharma, Inc. (REPH) Shares March Higher, Can It Continue? Zacks
Apr-16-19 07:00AM  Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville GlobeNewswire
Apr-11-19 04:05PM  Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting GlobeNewswire
Apr-04-19 10:58AM  Recro Pharma eliminates 50 jobs following FDA setback American City Business Journals +27.91%
07:58AM  The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut Benzinga
Apr-03-19 04:05PM  Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance GlobeNewswire
Mar-26-19 11:51AM  Recro Pharma Falls as FDA Denies Approval to Pain Candidate Zacks
Mar-25-19 04:29PM  Why Recro Pharma's stock price plunged more than 34% today American City Business Journals -34.04%
10:53AM  More Pain For Recro Pharma: FDA Rejects Meloxicam NDA For Second Time Benzinga
07:45AM  Recro Pharma's stock plunges to pace premarket decliners after 2nd CRL for pain treatment MarketWatch
07:00AM  Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors GlobeNewswire
Mar-22-19 04:33PM  FDA rejects Malvern pharma firm's non-opioid pain killer for a second time American City Business Journals
03:30PM  Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam GlobeNewswire
Mar-12-19 07:00AM  Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting GlobeNewswire
Mar-05-19 09:00AM  Options Traders Expect Huge Moves in Recro Pharma (REPH) Stock Zacks
Mar-04-19 07:00AM  Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility GlobeNewswire
Feb-25-19 04:05PM  Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development GlobeNewswire
Feb-21-19 11:59AM  Edited Transcript of REPH earnings conference call or presentation 19-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
Feb-20-19 07:00AM  Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine GlobeNewswire
Feb-19-19 07:24AM  Recro Pharma: 4Q Earnings Snapshot Associated Press
07:00AM  Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018 GlobeNewswire
06:00AM  Recro Pharma, Inc. to Host Earnings Call ACCESSWIRE
Feb-15-19 04:08PM  What's in the Cards for Bausch Health (BHC) Q4 Earnings? Zacks
Feb-14-19 12:58PM  5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings Zacks
07:00AM  Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019 GlobeNewswire
Feb-11-19 07:00AM  Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro Gainesville GlobeNewswire +5.43%
Jan-30-19 01:10PM  Could Recro Pharma, Inc.s (NASDAQ:REPH) Investor Composition Influence The Stock Price? Simply Wall St.
Jan-23-19 08:11AM  5 Domestic Stocks to Gain From Thaw in Trade Talks Zacks
Jan-02-19 07:00AM  Recro Pharma Amends Athyrium Credit Facility GlobeNewswire
Dec-21-18 11:32AM  Recro Pharma restructures licensing agreement for non-opioid pain medicine American City Business Journals
07:00AM  Recro Pharma Amends IV Meloxicam License Agreement with Alkermes GlobeNewswire
Dec-10-18 07:00AM  Recro Pharma Announces Presentation of New Data Demonstrating IV Meloxicams Effect on Platelet Function at the 72nd PostGraduate Assembly in Anesthesiology GlobeNewswire
Nov-27-18 01:23PM  Our Take On Recro Pharma Incs (NASDAQ:REPH) CEO Salary Simply Wall St.
Nov-20-18 09:52AM  Edited Transcript of REPH earnings conference call or presentation 7-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-16-18 08:20AM  Detailed Research: Economic Perspectives on StarTek, Plantronics, Akoustis Technologies, Genie Energy, Recro Pharma, and BIO-key International What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-14-18 07:00AM  Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia GlobeNewswire
Nov-08-18 07:00AM  Recro Pharma to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-07-18 11:00AM  Recro Pharma (REPH) Reports Q3 Loss, Tops Revenue Estimates Zacks
10:44AM  Recro Pharma: 3Q Earnings Snapshot Associated Press
07:00AM  Recro Pharma Reports Third Quarter 2018 Financial Results Raising Guidance for CDMO business for 2018 GlobeNewswire
Oct-31-18 07:00AM  Recro Pharma to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018 GlobeNewswire
Oct-09-18 04:19PM  FDA Sets Action Date for Recro's Pain Management Candidate Zacks
Oct-08-18 12:00PM  Take two: Recro tries for second time to get FDA approval for its non-opioid pain medicine American City Business Journals
07:00AM  Recro Pharma Announces PDUFA Date for IV Meloxicam GlobeNewswire
Oct-01-18 07:00AM  Recro Announces Expansion of CDMO Service Capabilities GlobeNewswire
Sep-10-18 07:00AM  Recro Pharma to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-05-18 07:00AM  Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018 GlobeNewswire +11.77%
Sep-04-18 10:50AM  Recro Pharma to resubmit application for non-opioid pain medicine American City Business Journals +26.49%
09:30AM  3 Stocks to Watch As The Healthcare Sector Heats Up ACCESSWIRE
07:00AM  Recro Pharma Provides Regulatory Update for IV Meloxicam GlobeNewswire
Aug-20-18 09:46PM  Edited Transcript of REPH earnings conference call or presentation 7-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-07-18 10:40AM  Recro Pharma (REPH) Reports Q2 Loss, Tops Revenue Estimates Zacks
09:33AM  Recro Pharma: 2Q Earnings Snapshot Associated Press
07:00AM  Recro Pharma Reports Second Quarter 2018 Financial Results GlobeNewswire
06:00AM  Recro Pharma, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-18 03:39PM  Recro Pharma Q2 Earnings Preview Benzinga
Jul-31-18 07:00AM  Recro Pharma to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018 GlobeNewswire
Jul-30-18 11:19AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TAL, QCOM, REVG, FLKS and REPH GlobeNewswire
10:42AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $50K of Class Action Against Recro Pharma, Inc. (REPH) & Lead Plaintiff Deadline: July 30, 2018 ACCESSWIRE
Jul-29-18 11:00AM  SHAREHOLDER ALERT: TAL ORA REVG FPI NWL PCG REPH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Jul-27-18 08:55PM  Glancy Prongay & Murray LLP Reminds Investors of Lead Plaintiff Deadline in the Class Action Lawsuit Against Recro Pharma, Inc. (REPH) GlobeNewswire
02:41PM  CLASS ACTION UPDATE for ORA and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:55PM  3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
10:38AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $50K of Class Action Against Recro Pharma, Inc. (REPH) & Lead Plaintiff Deadline: July 30, 2018 ACCESSWIRE
Jul-26-18 03:13PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MRCY, REVG and REPH GlobeNewswire
01:27PM  MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Jul-25-18 04:45PM  CLASS ACTION UPDATE for FIZZ, ACAD and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
04:40PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Recro Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - REPH ACCESSWIRE
02:10PM  5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
11:57AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TAL, ANW, DB, FIZZ and REPH GlobeNewswire
10:37AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Recro Pharma, Inc. (REPH) & Lead Plaintiff Deadline - July 30, 2018 ACCESSWIRE
Jul-24-18 04:00PM  CLASS ACTION UPDATE for QCOM, FLR, FPI and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:50PM  JULY 30 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:00AM  SHAREHOLDER ALERT: ATEN ANW DB QCOM FPI FIZZ SBGL ACAD FLR REPH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Jul-23-18 06:43PM  The Law Offices of Howard G. Smith Reminds Investors of July 30th Deadline in the Class Action Lawsuit Against Recro Pharma, Inc. (REPH) Business Wire
02:30PM  DEADLINE ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:57PM  CLASS ACTION UPDATE for ATEN, FLR and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:22PM  Important Stockholder Deadline Alert in Class Action Lawsuit Filed Against Recro Pharma, Inc. by Kaskela Law LLC GlobeNewswire
12:35PM  NOTICE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Recro Pharma, Inc.- REPH ACCESSWIRE
Recro Pharma, Inc. operates as a specialty pharmaceutical company. It operates through two divisions, an Acute Care, and Contract Development and Manufacturing (CDMO). The Acute Care division primarily focuses on developing products for the hospital and other acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has completed two pivotal Phase III clinical efficacy trials, a double-blind placebo-controlled Phase III safety trial, and four Phase II clinical efficacy trials, as well as other safety studies. Its pipeline also includes other early-stage product candidates, including two novel neuromuscular blocking agents and a related proprietary chemical reversal agent, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine or Dex an alpha-2 adrenergic agonist. The CDMO division leverages its formulation expertise to develop and manufacture pharmaceutical products using its proprietary delivery technologies and other manufacturing services for commercial and development-stage partners who commercialize or plan to commercialize these products. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ajdler ArnaudDirectorMay 17Buy9.0040,000360,0001,104,546May 21 04:11 PM
HENWOOD GERALDINEPresident and CEOMay 13Option Exercise2.47123,500305,045342,947May 15 04:06 PM
HENWOOD GERALDINEPresident and CEOMay 13Sale8.89144,8061,287,296198,141May 15 04:06 PM